MarketPulse
A

$AGMB

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Agomab Therapeutics Nv

Agomab Raises $208M in IPO, Extends Runway to 2029 Amid Pipeline Progress

Agomab Therapeutics raised $208M in February 2026 IPO and reported €116.5M cash, funding operations into H1 2029 while advancing two lead drug candidates.
AGMBIPOclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agomab Secures U.S. Patent for IPF Treatment AGMB-447 Through 2041

Agomab Therapeutics gains patent protection for AGMB-447, an inhaled lung-targeted therapy for idiopathic pulmonary fibrosis, with Phase 1b results expected in 2026.
AGMBintellectual propertyPhase 1b study